Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross‐Sectional Survey
George Bello, Alinune N. Kabaghe, Sherri Pals, Newton L. Kalata et autres
INTRODUCTION: Malawi began transitioning children living with HIV (CLHIV) to dolutegravir-based regimens (DBRs) in 2020, and 99.9% were on a DBR by September 2023. With nearly universal use of DBR, surveillance of HIV drug resistance (HIVDR) to dolutegravir is essential. We describe …
Malawi, Ouganda, us, gb (code pays fourni par la source)